[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,572
Citations 0
JAMA Clinical Evidence Synopsis
October 25, 2016

Interventions for Vitiligo

Author Affiliations
  • 1Department of Dermatology, Henri Mondor Hospital and EpiDermE, Université Paris-Est Créteil Val-de-Marne, Créteil, France
  • 2Cochrane Skin Group, Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, England
  • 3ISGlobal, Centre for Research in Environmental Epidemiology, Barcelona, Spain
JAMA. 2016;316(16):1708-1709. doi:10.1001/jama.2016.12399

Clinical Question  Which interventions are associated with highest efficacy and fewest adverse events for treating vitiligo?

Bottom Line  Combination therapies, particularly those involving some form of light (ie, narrowband UV-B) were associated with more improved repigmentation than monotherapies. There was limited evidence to support the association of UV-A alone and UV-B alone with repigmentation for vitiligo. There was moderate evidence to support the association of UV-A and UV-B, when used in combination with psoralens, topical corticosteroids, vitamin D analogues, fluorouracil, azathioprine, and oral prednisolone with improved outcomes for vitiligo. However, combination therapies were associated with more adverse effects.